XENE
Closed
Xenon Pharmaceuticals Inc
38.47
-1.38 (-3.46%)
Last Update: 06 Sep 2024 23:21:00
Yesterday: 39.85
Day's Range: 38.47 - 40.03
Send
sign up or login to leave a comment!
When Written:
35.22
Xenon Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the discovery and development of innovative therapeutics for rare neurological disorders. The company was founded in 1996 and is headquartered in Burnaby, British Columbia, Canada.
Xenon's core technology platform is based on the identification of disease-causing genes and the development of small molecule drugs that target these genes. The company has a pipeline of drug candidates in various stages of development, including XEN1101 for epilepsy and XEN496 for infantile spasms.
Xenon has partnerships with several pharmaceutical companies, including Genentech, Teva Pharmaceuticals, and Neurocrine Biosciences. The company is also involved in research collaborations with academic institutions and non-profit organizations.
In addition to its drug development programs, Xenon offers a range of services to support drug discovery and development, including genetic testing, preclinical drug development, and clinical trial management.
Xenon Pharmaceuticals Inc. is listed on the NASDAQ stock exchange under the ticker symbol "XENE".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Xenon's core technology platform is based on the identification of disease-causing genes and the development of small molecule drugs that target these genes. The company has a pipeline of drug candidates in various stages of development, including XEN1101 for epilepsy and XEN496 for infantile spasms.
Xenon has partnerships with several pharmaceutical companies, including Genentech, Teva Pharmaceuticals, and Neurocrine Biosciences. The company is also involved in research collaborations with academic institutions and non-profit organizations.
In addition to its drug development programs, Xenon offers a range of services to support drug discovery and development, including genetic testing, preclinical drug development, and clinical trial management.
Xenon Pharmaceuticals Inc. is listed on the NASDAQ stock exchange under the ticker symbol "XENE".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
35.22
Xenon Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the discovery and development of innovative therapeutics for diseases with high unmet medical needs. The company was founded in 1996 and is headquartered in Burnaby, British Columbia, Canada.
Xenon's focus is on developing drugs that target ion channels, which are proteins that control the flow of ions in and out of cells. The company's lead product candidate, XEN496, is a potential treatment for epilepsy that is currently in clinical development.
In addition to XEN496, Xenon has a pipeline of other product candidates in various stages of development for a range of diseases, including pain, cardiovascular disease, and rare genetic disorders.
Xenon has partnerships with several pharmaceutical companies, including Genentech, Teva Pharmaceuticals, and Ipsen, to develop and commercialize its product candidates.
The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "XENE."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Xenon's focus is on developing drugs that target ion channels, which are proteins that control the flow of ions in and out of cells. The company's lead product candidate, XEN496, is a potential treatment for epilepsy that is currently in clinical development.
In addition to XEN496, Xenon has a pipeline of other product candidates in various stages of development for a range of diseases, including pain, cardiovascular disease, and rare genetic disorders.
Xenon has partnerships with several pharmaceutical companies, including Genentech, Teva Pharmaceuticals, and Ipsen, to develop and commercialize its product candidates.
The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "XENE."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!